ACLX
Arcellx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$115.07
+0.02%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+63.9%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Apr 28, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | A-Award | 59,028 | $0.00 |
| Apr 28, 2026 | Elghandour Rami · director, officer: SEE REMARKS | A-Award | 138,888 | $0.00 |
| Apr 28, 2026 | Elghandour Rami · director, officer: SEE REMARKS | A-Award | 284,388 | $0.00 |
| Apr 28, 2026 | Elghandour Rami · director, officer: SEE REMARKS | A-Award | 147,745 | $0.00 |
| Apr 28, 2026 | Heery Christopher · officer: CHIEF MEDICAL OFFICER | A-Award | 45,138 | $0.00 |
| Apr 17, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | M-Exempt | 2,110 | $8.66 |
| Apr 17, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | M-Exempt | 36,000 | $8.66 |
| Feb 27, 2026 | Elghandour Rami · director, officer: SEE REMARKS | Sale | 89,916 | $114 |
| Feb 25, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | Sale | 11,219 | $114 |
| Feb 19, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | Sale | 100 | $69 |
| Feb 19, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | Sale | 5,405 | $69 |
| Feb 19, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | Sale | 2,879 | $68 |
| Feb 18, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | Sale | 4,150 | $70 |
| Feb 18, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | Sale | 7,141 | $69 |
| Jan 20, 2026 | Lubner David Charles · director | M-Exempt | 6,000 | $6.28 |
| Jan 20, 2026 | Lubner David Charles · director | Sale | 6,000 | $75 |
| Jan 14, 2026 | Heery Christopher · officer: CHIEF MEDICAL OFFICER | Sale | 5,882 | $69 |
| Jan 13, 2026 | Heery Christopher · officer: CHIEF MEDICAL OFFICER | Sale | 7,437 | $66 |
| Jan 12, 2026 | Heery Christopher · officer: CHIEF MEDICAL OFFICER | Sale | 6,131 | $64 |
| Jan 6, 2026 | Heery Christopher · officer: CHIEF MEDICAL OFFICER | M-Exempt | 16,520 | $0.00 |
| Jan 6, 2026 | Elghandour Rami · director, officer: SEE REMARKS | A-Award | 208,333 | $0.00 |
| Jan 6, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | A-Award | 88,542 | $0.00 |
| Jan 6, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | M-Exempt | 20,530 | $0.00 |
| Jan 6, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | M-Exempt | 15,340 | $0.00 |
| Jan 6, 2026 | Gilson Michelle · officer: CHIEF FINANCIAL OFFICER | M-Exempt | 20,496 | $0.00 |
| Jan 6, 2026 | Elghandour Rami · director, officer: SEE REMARKS | M-Exempt | 53,098 | $0.00 |
| Jan 6, 2026 | Elghandour Rami · director, officer: SEE REMARKS | M-Exempt | 55,459 | $0.00 |
| Jan 6, 2026 | Elghandour Rami · director, officer: SEE REMARKS | M-Exempt | 55,991 | $0.00 |
| Jan 6, 2026 | Heery Christopher · officer: CHIEF MEDICAL OFFICER | M-Exempt | 13,021 | $0.00 |
| Jan 6, 2026 | Heery Christopher · officer: CHIEF MEDICAL OFFICER | M-Exempt | 13,064 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 97Increased 61Reduced 61Sold out 239
| Filer | Action | Shares | Filed |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Unchanged | 6,720,803 | May 8, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 5,774,016 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 3,945,238 | May 13, 2026 |
| NEA MANAGEMENT COMPANY, LLC | Unchanged | 3,045,262 | May 15, 2026 |
| PENTWATER CAPITAL MANAGEMENT LP | New Position | 2,870,000 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 2,425,218 | May 15, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 2,424,818 | May 8, 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | Unchanged | 2,346,630 | May 14, 2026 |
| FIL LTD | New Position | 2,339,192 | May 15, 2026 |
| HBK INVESTMENTS L P | New Position | 2,278,517 | May 15, 2026 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | Reduced | 2,255,878 | May 15, 2026 |
| STATE STREET CORP | Reduced | 1,675,895 | May 15, 2026 |
| GLAZER CAPITAL, LLC | New Position | 1,511,570 | May 14, 2026 |
| GOLDMAN SACHS GROUP INC | Reduced | 1,365,155 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 1,028,666 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Apr 28, 2026